Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus DYNACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus DYNACIN.
ACTICLATE CAP vs DYNACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Dynacin (minocycline) is a semi-synthetic tetracycline antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to mRNA-ribosome complex. It also has anti-inflammatory and neuroprotective effects via inhibition of microglial activation, matrix metalloproteinases, and p38 MAPK signaling.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
100 mg orally twice daily or 200 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal elimination half-life 18-24 hours; prolonged in renal impairment (up to 50 hours in severe insufficiency). Steady state achieved in 4-5 days.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal (40-50% unchanged), hepatic metabolism (30-40% as metabolites), fecal (<10%).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic